Tag: neurological disorder drugs market segment

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Neurological Disorder Drugs Market From 2025 To 2029?

The market for drugs aimed at neurological disorders has witnessed significant expansion in the recent past. There is expected to be a growth from $84.6 billion in 2024 to about $90.09 billion in 2025. This growth rate, calculated annually, will compound to about 6.5%. This historical progress can be traced back to a rise in animal testing yielding hopeful results, the climb of therapeutic cures, the expansion of neurological issues, governmental drives, and an increase in spending in the healthcare sector.

What Is the Projected Market Size of the Neurological Disorder Drugs Market?

The market size for drugs related to neurological conditions is poised for robust growth in the coming years, expanding to $114.65 billion by 2029 with a compound annual growth rate (CAGR) of 6.2%. The projected growth in the forecast period is largely due to the rise in customized therapy options, an increased concentration on treatments that modify diseases, the wider application of digital biomarkers, and the growing incidence of neurological conditions. The anticipated trends in this forecast period comprise advancements in the designing of drugs, improvements in neuroimaging, progressed genetic research, increased collaborations and licensing agreements, along with the advent of regenerative medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Who are the Major Competitors in the Neurological Disorder Drugs Market Outlook?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

What Is Fueling Growth in the Neurological Disorder Drugs Market?

The growth of the neurological disorder drugs market is anticipated to be fueled by the rising prevalence of neurological diseases. These disorders are conditions that impact the brain, spinal cord, and nerves due to structural, biochemical, or electrical abnormalities, and they trigger varied symptoms. The uptick in the instances of such diseases is owed to an aging global populace and heightened exposure to environmental, metabolic, and lifestyle-related risk factors. Neurological disorder drugs are crucial in managing these complicated illnesses – they provide symptom relief, slow the disease evolution, and enhance patients’ long-term outcomes. For example, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in September 2024 that it is forecasted there will be a significant surge in dementia cases in Australia from 2023 to 2058. The count will likely more than double from roughly 411,100 in 2023 to 849,300 by 2058, affecting around 315,500 men and 533,800 women. Therefore, the upward trend of neurological disease prevalence fuels the expansion of the neurological disorder drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Which Neurological Disorder Drugs Market Segments Are Growing the Fastest?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Which Industry Trends Are Shaping the Future of the Neurological Disorder Drugs Market?

Leading firms in the neurological disorder drugs market are concentrating on the advancement of novel Ocrelizumab drug therapies to heighten treatment effectiveness, optimize patient results, and broaden treatment choices for people suffering from multiple sclerosis. Serving as a therapeutic drug in treating multiple sclerosis (MS), a form of neurological disorder, Ocrelizumab is a humanized monoclonal antibody. For instance, February 2024 saw the launch of Ocrevus (Ocrelizumab), a fresh disease-modifying therapy (DMT) drug for the treatment of multiple sclerosis, by Roche Holding AG, a Swiss-based pharmaceutical company, in India. Backed by more than a decade of clinical and real-world data, Ocrevus is the inaugural and solitary approved DMT for relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Ocrevus, a monoclonal antibody, targets CD20-positive B cells, which are conjectured to contribute to the autoimmune assault on the central nervous system in multiple sclerosis. It is applicable in treating both RRMS and PPMS, thereby being the first-ever approved drug for both these variants of the disease. Intravenously administered typically every six months, Ocrevus has manifested effectiveness in curbing disease activity and mitigating disability progression in clinical trials.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Countries Are Leading the Neurological Disorder Drugs Market?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17207

This Report Delivers Insight On:

1. How big is the neurological disorder drugs market, and how is it changing globally?

2. Who are the major companies in the neurological disorder drugs market, and how are they performing?

3. What are the key opportunities and risks in the neurological disorder drugs market right now?

4. Which products or customer segments are growing the most in the neurological disorder drugs market?

5. What factors are helping or slowing down the growth of the neurological disorder drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Neurological Disorder Drugs Market?

The increasing prevalence of neurological diseases is enhancing the neurological disorder drugs market. Aging and environmental risks are driving disease rates. Drugs manage symptoms and slow disease progression. In September 2024, the Australian Institute of Health and Welfare projected dementia cases to rise from 411,100 in 2023 to 849,300 by 2058. This growth is propelling the drug market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

#What is the Growth Potential of the Neurological Disorder Drugs Market, and How Will It Perform by 2034?

The neurological disorder drugs market size has shown significant growth in recent years. It will expand from $84.6 billion in 2024 to $90.09 billion in 2025 at a CAGR of 6.5%. This growth is linked to successful animal trials, new therapeutic developments, rising neurological conditions, supportive government policies, and increased healthcare spending.

The neurological disorder drugs market is expected to reach $114.65 billion in 2029, with a CAGR of 6.2%. The growth is attributed to expanding therapeutic options, disease-modifying treatments, digital biomarkers, and the rising prevalence of neurological diseases. Trends include advancements in drug design, neuroimaging, genetic research, collaborations, and regenerative medicine.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17207

What Are the Key Market Innovations in theNeurological Disorder Drugs Market Over the Coming Years?

Major companies in the neurological disorder drugs market are expanding treatment options with therapies like Ocrelizumab. In February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced Ocrevus (Ocrelizumab) in India for treating both relapsing-remitting and primary progressive multiple sclerosis. Administered biannually, it targets CD20-positive B cells, reducing disease activity and progression.

Who Are the Top Companies Driving Innovation and Growth in theNeurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Key Market Segments Comprise the Neurological Disorder Drugs Market and Drive Its Revenue Growth?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Which Regions Are Emerging as Leaders in the Neurological Disorder Drugs Market?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Neurological Disorder Drugs Market 2025, By The Business Research Company:

Myeloproliferative Disorders Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Neurological Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Bleeding Disorders Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Discover trends, market shifts, and competitive outlooks for the neurological disorder drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Neurological Disorder Drugs Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market size for drugs treating neurological disorders has seen significant expansion in the recent past. It is projected to experience a follow-on growth from $84.6 billion in 2024 to $90.09 billion in 2025, with a compound annual growth rate (CAGR) of 6.5%. This growth observed in the historical period is due to factors such as enhanced animal testing yielding optimistic results, a rise in therapeutic treatments, an escalation in the incidence of neurological issues, initiatives undertaken by the government, and an increase in healthcare spending.

Predictions indicate marked escalation in the size of the neurological disorder medication market in the forthcoming years, with estimations reaching $114.65 billion in 2029, progressing at a Compound Annual Growth Rate (CAGR) of 6.2%. The anticipated expansion over the forecasted period is associated with the evolution of therapeutic alternatives and personalized treatments, increased concentration on disease-modifying solutions, rising utilization of digital biomarkers, and growing incidences of neurological disorders. Significant trends expected during this forecast period incorporate progressions in drug architecture, developments in neuroimaging, breakthroughs in genetic studies, strategic collaborations and licensing agreements, as well as the introduction of regenerative medicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Neurological Disorder Drugs Market?

The growth of the neurological disorder drugs market is projected to be driven by the growing incidence of neurological conditions. These ailments, which are characterized by abnormalities in the brain, spinal cord or nerves’ structure, chemistry or electricity, have diverse symptoms. The surge in such disorders can be linked to global aging and increased exposure to environmental, metabolic and lifestyle hazards. The drugs used to treat these neurological disorders are crucial to their control, providing symptom relief, slowing down the progression of the disease and enhancing patients’ long-term wellbeing. For example, the Australian Institute of Health and Welfare, a government agency in Australia, forecasted in September 2024 that the population living with dementia in Australia will more than double from about 411,100 in 2023 to 849,300 by 2058, with approximately 315,500 men and 533,800 women affected. As a result, the growing incidence of neurological diseases is fuelling the expansion of the neurological disorder drugs market.

Which Segments in the Neurological Disorder Drugs Offer the Most Growth?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Which Areas Are Leading Regions in the Neurological Disorder Drugs Market Expansion Across the Globe?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in the Neurological Disorder Drugs Market Over the Coming Years?

Significant players in the neurological disorder drugs market are currently emphasizing on the creation of novel Ocrelizumab drug therapies. Their goal is to improve the efficiency of treatment, enhance the results for patients, and broaden the range of therapeutic choices for those suffering from multiple sclerosis. Ocrelizumab is a specialized monoclonal antibody utilized as a medicinal drug for treating multiple sclerosis (MS), a neurological disorder variant. For example, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical manufacturer, introduced Ocrevus (Ocrelizumab), a fresh disease-altering therapy (DMT) drug for the treatment of multiple sclerosis in India. Ocrevus holds the distinction of being the first and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), backed by a decade of clinical and practical data. This monoclonal antibody specifically targets CD20-positive B cells, thought to contribute to the autoimmune assault on the central nervous system in cases of multiple sclerosis (MS). Ocrevus is used to address both RRMS and PPMS, establishing it as the first medication approved for both variations of the condition. The drug is usually provided through intravenous methods every six months and has demonstrated effectiveness in minimizing disease activity and halting disability progression in clinical studies.

View the full report here:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

What Are the Key Elements That Define the Neurological Disorder Drugs Market?

Neurological disorder drugs refer to medications used to treat disorders of the nervous system. These disorders can affect the brain, spinal cord, and nerves throughout the body. The drugs aim to manage symptoms, slow the progression of the disorder, and improve the quality of life for individuals affected.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17207

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the neurological disorder drugs market?

Over the past few years, the neurological disorder drugs market has experienced substantial growth. Its market size is anticipated to escalate from $84.6 billion in 2024 to $90.09 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.5%. The historical growth can be credited to factors such as an increase in animal testing yielding promising outcomes, a surge in therapeutic treatments, a rise in neurological disorders, government-driven initiatives, and an overall increase in spending on healthcare.

What will be the neurological disorder drugs market size in the future?

Anticipated to witness significant expansion in the coming years, the market for neurological disorder drugs is predicted to escalate to a value of $114.65 billion by 2029, advancing at a compound annual growth rate (CAGR) of 6.2%. This forecasted growth could be driven by factors such as broadening therapeutic alternatives and customized treatments, heightened attention towards disease-altering therapies, widened adoption of digital biomarkers, and a rise in cases of neurological disorders. Prominent trends for the projected timeframe encompass progress in drug formation, breakthroughs in neuroimaging, advancements in the field of genetic studies, cooperative endeavors and licensing contracts, and the introduction of regenerative medicine.

Get your neurological disorder drugs market report here!

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

What main drivers are fueling expansion in the neurological disorder drugs market?

The escalation in the incidence of neurological disorders is predicted to fuel the expansion of the neurological disorder drugs market. These disorders, which encompass conditions that affect the brain, spinal cord, and nerves due to structural, biochemical, or electrical abnormalities, lead to diverse symptoms. The global rise in neurological diseases is linked to the aging adult population and higher exposure to environmental, metabolic, and lifestyle-related risk factors. Drugs for neurological disorders are paramount in handling these complicated conditions, providing symptom relief, decelerating disease advancement, and enhancing patient prognosis over time. For example, the Australian Institute of Health and Welfare, a government agency in Australia, projected in September 2024 that the population of dementia patients in Australia would more than double from 2023 to 2058, rising from about 411,100 in 2023 to 849,300 by 2058, affecting approximately 315,500 men and 533,800 women. Consequently, the rise in the prevalence of neurological ailments is spurring the growth of the neurological disorder drugs market.

What key areas define the segmentation of the global neurological disorder drugs market?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Who are the dominant players expanding their reach in the neurological disorder drugs market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

What are the key trends shaping the future of the neurological disorder drugs market?

Top corporations in the drugs market for neurological disorders are prioritizing the creation of novel Ocrelizumab drug therapies. Such groundbreaking therapies aim to not only make treatments more effective but also raise patient health results and broaden the range of treatments available to those diagnosed with multiple sclerosis. Known as a human monoclonal antibody, Ocrelizumab is employed as a medicinal drug to address multiple sclerosis, a variety of neurological disorder. In February 2024, for example, Roche Holding AG, a pharmaceutical firm hailing from Switzerland, introduced Ocrevus (Ocrelizumab) in India as a cutting-edge disease-modifying therapy (DMT) drug purposed for the treatment of multiple sclerosis. Ocrevus, the first DMT approved for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), is backed by over a decade of data from clinical and real-world applications. This monoclonal antibody targets CD20-positive B cells, suspected contributors to the autoimmune assault on the central nervous system in multiple sclerosis (MS) cases. Ocrevus is approved for treating both RRMS and PPMS, cementing its position as the first drug sanctioned for both types of the condition. Administered intravenously approximately twice a year, Ocrevus has demonstrated effectiveness in lowering disease activity and slowing the progression of disability as seen in clinical trials.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17207

Which regions are emerging as leaders in the neurological disorder drugs market?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Myeloproliferative Disorders Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Neurological Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Bleeding Disorders Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the neurological disorder drugs market?

Over the past few years, the neurological disorder drugs market has experienced substantial growth. Its market size is anticipated to escalate from $84.6 billion in 2024 to $90.09 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.5%. The historical growth can be credited to factors such as an increase in animal testing yielding promising outcomes, a surge in therapeutic treatments, a rise in neurological disorders, government-driven initiatives, and an overall increase in spending on healthcare.

What will be the neurological disorder drugs market size in the future?

Anticipated to witness significant expansion in the coming years, the market for neurological disorder drugs is predicted to escalate to a value of $114.65 billion by 2029, advancing at a compound annual growth rate (CAGR) of 6.2%. This forecasted growth could be driven by factors such as broadening therapeutic alternatives and customized treatments, heightened attention towards disease-altering therapies, widened adoption of digital biomarkers, and a rise in cases of neurological disorders. Prominent trends for the projected timeframe encompass progress in drug formation, breakthroughs in neuroimaging, advancements in the field of genetic studies, cooperative endeavors and licensing contracts, and the introduction of regenerative medicine.

Get your neurological disorder drugs market report here!

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

What main drivers are fueling expansion in the neurological disorder drugs market?

The escalation in the incidence of neurological disorders is predicted to fuel the expansion of the neurological disorder drugs market. These disorders, which encompass conditions that affect the brain, spinal cord, and nerves due to structural, biochemical, or electrical abnormalities, lead to diverse symptoms. The global rise in neurological diseases is linked to the aging adult population and higher exposure to environmental, metabolic, and lifestyle-related risk factors. Drugs for neurological disorders are paramount in handling these complicated conditions, providing symptom relief, decelerating disease advancement, and enhancing patient prognosis over time. For example, the Australian Institute of Health and Welfare, a government agency in Australia, projected in September 2024 that the population of dementia patients in Australia would more than double from 2023 to 2058, rising from about 411,100 in 2023 to 849,300 by 2058, affecting approximately 315,500 men and 533,800 women. Consequently, the rise in the prevalence of neurological ailments is spurring the growth of the neurological disorder drugs market.

What key areas define the segmentation of the global neurological disorder drugs market?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Who are the dominant players expanding their reach in the neurological disorder drugs market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

What are the key trends shaping the future of the neurological disorder drugs market?

Top corporations in the drugs market for neurological disorders are prioritizing the creation of novel Ocrelizumab drug therapies. Such groundbreaking therapies aim to not only make treatments more effective but also raise patient health results and broaden the range of treatments available to those diagnosed with multiple sclerosis. Known as a human monoclonal antibody, Ocrelizumab is employed as a medicinal drug to address multiple sclerosis, a variety of neurological disorder. In February 2024, for example, Roche Holding AG, a pharmaceutical firm hailing from Switzerland, introduced Ocrevus (Ocrelizumab) in India as a cutting-edge disease-modifying therapy (DMT) drug purposed for the treatment of multiple sclerosis. Ocrevus, the first DMT approved for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), is backed by over a decade of data from clinical and real-world applications. This monoclonal antibody targets CD20-positive B cells, suspected contributors to the autoimmune assault on the central nervous system in multiple sclerosis (MS) cases. Ocrevus is approved for treating both RRMS and PPMS, cementing its position as the first drug sanctioned for both types of the condition. Administered intravenously approximately twice a year, Ocrevus has demonstrated effectiveness in lowering disease activity and slowing the progression of disability as seen in clinical trials.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17207

Which regions are emerging as leaders in the neurological disorder drugs market?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Myeloproliferative Disorders Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Neurological Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Bleeding Disorders Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Long-Term Growth Rate is Expected for the Neurological Disorder Drugs Market Between 2025 and 2034?

The market size for drugs treating neurological disorders has seen formidable growth in the previous years. The market, valued at $84.6 billion in 2024, is predicted to expand to $90.09 billion in 2025, signaling a compound annual growth rate (CAGR) of 6.5%. Factors influencing this growth during the historical period encompass an increase in animal experimentation yielding positive results, heightened therapeutic treatment interventions, rising occurrences of neurological issues, government-backed initiatives, and an uptick in healthcare spending.

The market size for drugs treating neurological disorders is projected to witness significant expansion in the next couple of years, reaching an impressive worth of $114.65 billion by 2029. This represents a compound annual growth rate (CAGR) of 6.2%. Several factors contribute to this upward trend during the forecasted period such as advances in personalized treatments and therapeutic options, emphasis on disease-modifying treatments, wider adoption of digital biomarkers, and the escalating rates of neurological diseases. Noteworthy trends within this period include improvements in drug development, breakthroughs in neuroimaging and genetic research, licensing partnerships and agreements, coupled with the rise of regenerative medicine.

Which Macro and Microeconomic Factors Are Accelerating the Growth of the Neurological Disorder Drugs Market?

The surge in instances of neurological diseases is anticipated to power the expansion of the neurological disorder drugs market. This span of ailments, affecting the brain, spine, and nerves, are the result of structural, biochemical, or electrical abnormalities, manifesting in varied symptoms. The rise in neurological maladies can be traced back to an ageing global populace and an amplified exposure to environmental, metabolic, and lifestyle threats. Drugs specifically aimed at neurological disorders are pivotal in handling these convoluted conditions, providing symptom relief, hampering disease progression and enhancing long-term patient outcomes. As an example, the Australian Institute of Health and Welfare, a government agency based in Australia, predicted in September 2024 that by 2058, the number of individuals suffering from dementia in Australia would more than double from about 411,100 in 2023 to an estimated 849,300. This population will comprise roughly315,500 men and 533,800 women. Consequently, the burgeoning prevalence of neurological ailments is fuelling the expansion of the neurological disorder drugs market.

Explore Comprehensive Insights Into The Global Neurological Disorder Drugs Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What Are the Key Firms That Are Driving Transformation in the Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are:

• F. Hoffmann-La Roche Ltd_x000D_

• Bayer AG_x000D_

• Sanofi S.A_x000D_

• AstraZeneca PLC_x000D_

• Abbott Laboratories_x000D_

What Current Trends in the Neurological Disorder Drugs Market Should Industry Players Pay Attention To?

Major pharmaceutical firms active in the neurological disorder drugs market are concentrating on creating innovative therapies using Ocrelizumab to boost treatment effectiveness, enhance patient results, and broaden therapy choices for those with multiple sclerosis. As a humanized monoclonal antibody, Ocrelizumab is utilised in medically treating multiple sclerosis (MS), a type of neurological condition. For instance, Roche Holding AG, a Swiss pharmaceutical enterprise, introduced Ocrevus (Ocrelizumab) in India in February 2024. This is a fresh disease-modifying therapy (DMT) for people with multiple sclerosis. Ocrevus, backed by over 10 years of clinical and real-world evidence, is the first-ever DMT to receive approval for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). As a monoclonal antibody, it targets CD20-positive B cells considered to be involved in the auto-immune assault on the nervous system in MS cases. It is used to address both forms of the disease, RRMS and PPMS, thus becoming the first drug to receive approval for these MS types. It is generally administered intravenously every six months and its clinical trials have demonstrated effectiveness in reducing disease activity and slowing down disability progression.

Secure Your Global Neurological Disorder Drugs Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

How Are the Key Segments of the Neurological Disorder Drugs Market Impacting Its Expansion and Revenue Streams?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Regions Are Driving Expansion in the Neurological Disorder Drugs Market?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Does the Definition of the Neurological Disorder Drugs Market Include?

Neurological disorder drugs refer to medications used to treat disorders of the nervous system. These disorders can affect the brain, spinal cord, and nerves throughout the body. The drugs aim to manage symptoms, slow the progression of the disorder, and improve the quality of life for individuals affected.

Browse Through More Similar Reports By The Business Research Company:

Myeloproliferative Disorders Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Neurological Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Bleeding Disorders Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

How Much Growth is Expected for the Neurological Disorder Drugs Market from 2024 to 2033?

The neurological disorder drugs market size has seen significant growth in recent years. It is expected to expand from $79.67 billion in 2023 to $84.60 billion in 2024, achieving a CAGR of 6.2%. This growth is driven by increased animal testing with promising results, more therapeutic treatments, a rise in neurological issues, government initiatives, and growing healthcare expenditures.

The neurological disorder drugs market size is forecasted to see substantial growth, reaching $108.05 billion by 2028, with a CAGR of 6.3%. This growth is attributed to the expansion of therapeutic options and personalized treatments, an increasing emphasis on disease-modifying therapies, the broader use of digital biomarkers, and the rising prevalence of neurological disorders. Major trends anticipated include innovations in drug design, advancements in neuroimaging, progress in genetic research, collaborations and licensing deals, and the emergence of regenerative medicine.

What Factors Are Encouraging Growth in the Neurological Disorder Drugs Market?

The growing prevalence of neurological diseases is projected to propel the neurological disorder drugs market. Neurological disorders affect the brain, spinal cord, and nerves due to structural, biochemical, or electrical abnormalities, resulting in various symptoms. The increase in these diseases is linked to an aging global population and greater exposure to environmental, metabolic, and lifestyle risk factors. Drugs for neurological disorders are crucial for managing these complex conditions, providing symptom relief, slowing disease progression, and improving long-term patient outcomes. For instance, a report by the UK Parliament indicated that the number of people waiting for neurology treatment rose to 140,482 in June 2021, up from 134,245 in May 2021. Therefore, the rising prevalence of neurological diseases is driving the neurological disorder drugs market.

Claim Your Free Sample of the Global Neurological Disorder Drugs Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Which Segments Play a Vital Role in the Neurological Disorder Drugs Market?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

What Trends Are Driving Change in the Neurological Disorder Drugs Market?

Major companies in the neurological disorder drugs market are focused on developing Ocrelizumab therapies to improve treatment efficacy for multiple sclerosis. In February 2024, Roche Holding AG, a Swiss pharmaceutical company, launched Ocrevus, a new disease-modifying therapy for MS, approved for both relapsing-remitting and primary progressive forms of the disease.

Order Now for Fast Delivery of Your Neurological Disorder Drugs Market Report!

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

What Regions Are Contributing Significantly to the Growth of the Neurological Disorder Drugs Market?

North America was the largest region in the neurological disorder drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Neurological Disorder Drugs Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the neurological disorder drugs market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Neurological Disorder Drugs Market Include

1. Neurological Disorder Drugs Market Executive Summary
2. Neurological Disorder Drugs Market Segments
3. Neurological Disorder Drugs Market Size And Template Market Growth Rate
4.  Key Neurological Disorder Drugs Market Trends
5. Major Neurological Disorder Drugs Market Drivers
……
25. Key Mergers And Acquisitions In The Neurological Disorder Drugs Market
26. Top Neurological Disorder Drugs Companies
27. Neurological Disorder Drugs Market Opportunities And Strategies
28. Neurological Disorder Drugs Market, Conclusions And Recommendations
29. Appendix

Discover Related Reports by The Business Research Company:

Rare Neurological Disease Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Neurological Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

HPV Associated Disorders Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The neurological disorder drugs market is experiencing significant growth, driven by an increase in neurological diseases, advancements in treatment options, and strategic industry moves. This blog will explore the current market size, future growth forecasts, major drivers, key players, and emerging trends.

Market Size and Growth Rate

2024 Market Size:

• The market for neurological disorder drugs is projected to grow from $79.67 billion in 2023 to $84.60 billion in 2024.
• CAGR: 6.2%, reflecting strong market momentum.

Growth Drivers:

• Increase in therapeutic treatments.
• Growth in neurological problems.
• Rising healthcare expenditures.
• Government initiatives.

Future Growth Forecast

2028 Market Size:

• Expected to reach $108.05 billion by 2028.
• CAGR: 6.3%, indicating sustained market growth.

View More On The Neurological Disorder Drugs Market Report 2024 – https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Key Factors:

• Expansion of personalized therapies.
• Growing focus on disease-modifying treatments.
• Increasing use of digital biomarkers.
• Continued prevalence of neurological diseases.

Emerging Trends:

• Advancements in drug design and neuroimaging.
• Progress in genetic research.
• Collaboration and licensing agreements.
• Emergence of regenerative medicine.

Market Drivers: Rising Neurological Disorders

Increasing Prevalence:

• Impact: Growing cases of neurological diseases, including Alzheimer’s, Parkinson’s, and multiple sclerosis, are major market drivers.
• Contributing Factors: Aging population, lifestyle changes, and environmental risk factors.

Market Role:

• Neurological disorder drugs are essential for managing complex conditions, relieving symptoms, and improving patient outcomes.

Key Players in the Global Market

Leading Companies:

• Pharmaceutical Giants: F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories.
• Others: Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical, Eli Lilly and Company, Amgen Inc.

Strategic Importance:

• These companies are at the forefront of drug development, market expansion, and innovation, driving the industry forward.

Trends in Neurological Disorder Drugs

Innovative Treatments for Multiple Sclerosis:

• Focus: Major companies are developing innovative drug therapies like Ocrelizumab for multiple sclerosis.
• Example: In February 2024, Roche launched Ocrevus (Ocrelizumab) in India, a treatment for both relapsing-remitting and primary progressive multiple sclerosis.
• Significance: This is the first drug approved for both forms of MS, showing efficacy in reducing disease activity and progression.

Mergers and Acquisitions: Strengthening Market Position

Pfizer’s Strategic Move:

• Acquisition: In October 2022, Pfizer acquired Biohaven Pharmaceuticals for $11.6 billion.
• Objective: Strengthen leadership in migraine treatments by gaining access to Biohaven’s calcitonin gene-related peptide portfolio.
• Impact: Enhances Pfizer’s internal medicine pipeline and global reach, targeting over 1 billion people affected by migraines.

Market Segmentation

By Drug Class:

• Cholinesterase Inhibitors, NMDA Receptor Antagonists, Antiepileptic, Antipsychotic, and Antidepressant.

By Indication:

• Epilepsy, Alzheimer’s, Parkinson’s, Multiple Sclerosis, Cerebrovascular Disease.

By Route of Administration:

• Oral, Parenteral, Other Routes.

By Distribution Channel:

• Hospital, Retail, Online Pharmacies.

By End-Users:

• Hospitals, Specialty Clinics, Homecare.

Regional Insights

North America:

• Market Leader: Largest region in the neurological disorder drugs market in 2023.
• Growth Factors: High healthcare expenditure, advanced research, and strong presence of key players.

Asia-Pacific:

• Growth Potential: Expected to be the fastest-growing region during the forecast period.
• Drivers: Increasing healthcare investments, growing awareness, and expanding market access.

Conclusion

The neurological disorder drugs market is on a robust growth trajectory, driven by rising neurological diseases, innovative treatment options, and strategic acquisitions. As the industry continues to evolve, key players and emerging trends will shape the future of neurological disorder treatments, offering hope for improved patient outcomes and expanding global market opportunities.

Request A Sample Of The Global Neurological Disorder Drugs Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=17207&type=smp